OTSUKA PHARMACEUTICAL CO., LTD.

OTSUKA PHARMACEUTICAL CO., LTD. logo
🇯🇵Japan
Ownership
Public, Subsidiary
Established
1964-01-01
Employees
101
Market Cap
-
Website
http://www.otsuka.co.jp
Clinical Trials
Related News

Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

First Posted Date
2017-08-18
Last Posted Date
2021-07-28
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
61
Registration Number
NCT03254108

Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

Completed
Conditions
Autism
First Posted Date
2017-06-07
Last Posted Date
2021-09-16
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
528
Registration Number
NCT03179787
Locations
🇯🇵

Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

First Posted Date
2017-02-09
Last Posted Date
2020-11-02
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
16
Registration Number
NCT03048747

Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: OPA-15406
Drug: Placebos
First Posted Date
2017-01-12
Last Posted Date
2020-07-23
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
73
Registration Number
NCT03018691

A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects

Phase 1
Completed
Conditions
Healthy Adult Male
Interventions
Drug: OPC-41061
First Posted Date
2016-12-15
Last Posted Date
2021-06-28
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
84
Registration Number
NCT02994394

Study of OPA-15406 Ointment in Patients With Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: OPA-15406
Drug: Placebo
First Posted Date
2016-09-26
Last Posted Date
2020-07-23
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
200
Registration Number
NCT02914548

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Adult Male
Interventions
Drug: OPC-34712
First Posted Date
2016-08-23
Last Posted Date
2021-02-23
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
18
Registration Number
NCT02875080

Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

First Posted Date
2016-07-28
Last Posted Date
2023-12-27
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
1672
Registration Number
NCT02847624
Locations
🇯🇵

Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan

A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects

Phase 1
Completed
Conditions
Alcohol Dependence
Interventions
Drug: nalmefene hydrochloride 10 mg
First Posted Date
2016-02-10
Last Posted Date
2017-04-18
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
7
Registration Number
NCT02679469
Locations
🇯🇵

Kyusyu, Region, Japan

Pharmacodynamic Study of Cilostazol in Healthy Volunteers

First Posted Date
2015-09-18
Last Posted Date
2021-10-13
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
77
Registration Number
NCT02554721
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy